Novo Nordisk nails another phase III study of once-weekly insulin
Results from a late-stage study of insulin icodec show that type 2 diabetes patients were better off on the Danish drugmaker’s experimental drug combined with an app solution than with standard treatment.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
On Monday, Novo Nordisk announced a success, reporting positive top-line results for a phase IIIa trial of once-weekly insulin icodec in a company press release.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.